Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results Director departure
|
Kezar Life Sciences, Inc. (KZR)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/03/2023 |
8-K
| Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm... |
08/10/2023 |
8-K
| Quarterly results |
07/26/2023 |
8-K
| Quarterly results |
06/16/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
05/11/2023 |
8-K
| Quarterly results |
04/27/2023 |
8-K
| Quarterly results |
02/28/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
01/09/2023 |
8-K
| Results of Operations and Financial Condition Interactive Data |
11/10/2022 |
8-K
| Quarterly results |
11/03/2022 |
8-K
| Quarterly results |
08/11/2022 |
8-K
| Quarterly results |
07/11/2022 |
8-K
| Quarterly results |
06/27/2022 |
8-K
| Quarterly results |
06/16/2022 |
8-K
| Quarterly results |
05/13/2022 |
8-K
| Quarterly results |
05/12/2022 |
8-K
| Quarterly results |
05/03/2022 |
8-K
| Quarterly results |
03/17/2022 |
8-K
| Quarterly results
Docs:
|
"Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update • Topline data from two Phase 2 trials of KZR-616 expected in second quarter of 2022 • Zetomipzomib assigned as nonproprietary name for lead candidate, KZR-616 • Cash, cash equivalents and marketable securities totaled $208.4 million as of year-end 2021 SOUTH SAN FRANCISCO, Calif. – – March 17, 2022 – Kezar Life Sciences, Inc., , a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a business update. “In 2021, we made significant progress in each of our programs, achieving target enrollmen..." |
|
01/07/2022 |
8-K
| Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment... |
12/20/2021 |
8-K
| Termination of a Material Definitive Agreement, Results of Operations and Financial Condition Interactive Data |
12/10/2021 |
8-K
| Quarterly results |
11/19/2021 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Results of Operations and Financi... |
11/15/2021 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
11/09/2021 |
8-K
| Quarterly results |
08/12/2021 |
8-K
| Quarterly results |
06/30/2021 |
8-K
| Quarterly results |
06/02/2021 |
8-K
| Quarterly results |
06/01/2021 |
8-K
| Quarterly results |
05/12/2021 |
8-K
| Quarterly results |
03/11/2021 |
8-K
| Quarterly results |
01/11/2021 |
8-K
| Quarterly results |
11/05/2020 |
8-K
| Quarterly results |
08/05/2020 |
8-K
| Quarterly results |
06/26/2020 |
8-K
| Quarterly results |
|
|
|